Developer docs
API playgroundTry for free, no card

Search company profiles

Ysios Capital

Full company profile

uuid000066o

Namestring
Ysios Capital
Legal namestring
Ysios Capital Partners, S.G.E.I.C., S.A.U.
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Ysios Capital Partners, S.G.E.I.C., S.A.U. is a Spanish life sciences venture capital firm founded in 2008 and headquartered in San Sebastián, with a second office in Barcelona. The firm provides private equity financing to early- and mid-stage biotechnology, medical device, diagnostics, and digital therapeutics companies developing therapies for indications with high unmet medical need, with portfolio companies located across Europe and the United States. Ysios manages over €400 million in assets across three venture capital funds, acts as investment advisor to the listed Telescope Biotech Fund managed by Andbank Wealth Management, and in March 2026 launched InceptionBio, a €100 million target-size fund focused on biotech company creation in Spain in partnership with CDTI.

The firm invests across the full life sciences value chain, from academic spin-offs (e.g., IRB Barcelona/ICREA spin-offs Inbiomotion and Ona Therapeutics) through clinical-stage and NASDAQ-listed companies (Aura Biosciences, Fusion Pharmaceuticals, KALA BIO, LAVA Therapeutics, Mineralys Therapeutics), with a portfolio of 42+ companies, 19 products brought to market, and over 70 products at clinical stage. Ysios has completed six NASDAQ exits and ten M&A transactions, including Takeda's acquisition of TiGenix (~€450M), Vifor Pharma's acquisition of Sanifit (€375M), and Qiagen's purchase of STAT-Diagnostica (€172M).

Revenue is generated through management fees on its three VC funds and the InceptionBio vehicle, plus investment advisory fees on the listed Telescope Biotech Fund, with potential carried interest participation through portfolio exits. The firm operates a proprietary Y-mpact impact measurement methodology with a public Y-Score assessment tool (1-5 stars across Innovation, Social, and Governance pillars), and is supported by the European Investment Fund (EIF), CDTI, and the European Union. Distribution is conducted through direct project submissions, direct investment with board representation, public-private co-investment via CDTI's SICC Innvierte program, and wealth-management distribution via Andbank.

Short descriptiontext

Ysios Capital is a Spanish life sciences venture capital firm founded in 2008 that provides private equity financing to early- and mid-stage biotech, medical device, and diagnostics companies across Europe and the United States, managing over €400M across three VC funds plus the InceptionBio company-creation fund.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech private equity, venture capital funds, biotech company creation, healthcare growth equity
Industry2 codes
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Funds, Trusts, and Other Financial Vehicles525
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Venture Capital
Social media profiles2 records
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Fund Management Fees
TypeManaged Services
Description

Ysios Capital generates revenue through management fees on three venture capital funds with over €400 million in assets under management, plus investment advisory fees on the Telescope Biotech Fund (a listed biotech fund managed by Andbank Wealth Management). A new €100 million target-size fund (InceptionBio) was launched in March 2026, with first closing already completed via CDTI's SICC Innvierte program.

ysioscapital.com
2Carried Interest / Fund Returns
TypeLicensing Royalties
Description

As a venture capital firm, Ysios Capital participates in fund returns through exits in its portfolio companies. The firm has completed six NASDAQ exits and ten M&A transactions, including landmark deals such as Takeda's acquisition of Tigenix (approximately €450M), Qiagen's purchase of STAT-Diagnostica (€172M), and Vifor Pharma's acquisition of Sanifit (€375M).

ysioscapital.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Fund terms and management fees are not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Ysios Capital manages over €400 million through three venture capital funds. The InceptionBio fund targets €100 million and has completed its first closing. The Telescope Biotech Fund is a listed biotech fund managed by Andbank Wealth Management with Ysios as investment advisor.

ysioscapital.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Y-mpact
Description

Ysios' proprietary in-house methodology to measure the impact of investment activity across Innovation, Social and Governance (ISG) pillars.

ysioscapital.com
+2 more records
Core offering1 text field

Ysios Capital is a European life sciences venture capital firm that provides private equity financing to early- and mid-stage biotech companies developing novel therapies for indications with high unmet medical need. It manages over €400 million across three venture capital funds, supplements this with a €100M InceptionBio company-creation fund, and acts as investment advisor to the listed Telescope Biotech Fund managed by Andbank Wealth Management. The firm combines capital with scientific, financial and operational expertise, supported by a proprietary Y-mpact impact measurement methodology.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ysios Capital is a Spanish/European life sciences venture capital firm whose offering is a platform-plus-modules investment architecture rather than a single SaaS product: (a) the core product is its three venture capital funds providing private equity financing to early- and mid-stage life sciences companies, supplemented by the InceptionBio €100M company-creation fund launched in March 2026 and the Telescope Biotech Fund advisory mandate; (b) proprietary differentiated capabilities include the in-house Y-mpact / Y-Score impact measurement methodology and public Y-Score Test tool, and the Whistleblowing Channel compliance service operated under Spanish Act 2/2023; and (c) supporting infrastructure includes the Valuat-based investor portal at ysios.valuat.com for fund reporting. These offerings collectively span the full life sciences investment value chain — from company creation through clinical-stage development — and serve limited partners/investors, portfolio companies and internal compliance stakeholders.

Product and service6 records
1InceptionBio fund
CategoryInvestment fund (company creation)
Description

New €100M target-size fund launched in March 2026 focused on biotech company creation and early-stage projects in Spain, co-led by Managing Partner Joan Perelló and Partner Arturo Urrios, with first closing via CDTI SICC Innvierte. Aims to create at least three new biotech companies in 2026 by working with universities, research centers and scientific entrepreneurs on technology transfer.

2Ysios Capital venture capital funds (three funds)
CategoryCore investment product (venture capital funds)
Description

Core private equity product providing financing to early- and mid-stage highly innovative life sciences companies developing therapies for indications with high unmet medical need. Manages over €400 million in assets across three venture capital funds and has invested in more than 40 biotech companies, achieving six NASDAQ exits and ten M&A transactions (Tigenix/Takeda ~€450M, STAT-Diagnostica/Qiagen €172M, Sanifit/Vifor €375M).

3Telescope Biotech Fund
CategoryAdvisory mandate (listed biotech fund)
Description

Listed biotech fund managed by Andbank Wealth Management for which Ysios Capital acts as investment advisor, complementing its direct venture capital investment strategy. Distributed via Andbank's wealth management platform.

4Y-mpact / Y-Score impact measurement
CategoryProprietary impact measurement methodology and tool
Description

In-house proprietary methodology that measures the impact of Ysios's investment activity across three pillars — Innovation, Social and Governance (ISG) — producing a Y-Score rated from 1 (low) to 5 (very high) stars per pillar and as a weighted overall score. Includes a public-facing Y-Score Test questionnaire accessible at ysioscapital.com/measure-your-y-score/.

5Whistleblowing Channel
CategoryCompliance / Governance service
Description

Internal reporting system implemented under Spanish Act 2/2023 (transposing EU Directive 2019/1937), enabling confidential and anonymous reporting of regulatory breaches, with Wen Wen Cheng (Head of Legal) appointed as Whistleblowing Channel Manager. Covers Ysios, its venture capital funds and managed closed-end collective investment schemes.

6Investor portal (Valuat)
CategoryInvestor portal / access platform
Description

Secure online login portal at ysios.valuat.com that provides Ysios Capital investors with access to fund and portfolio reporting.

Scale indicator19 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-05-26
Description

Clinical trial collaboration and supply agreement with Ysios portfolio company Adcendo ApS. MSD provides pembrolizumab (KEYTRUDA®) to be evaluated in combination with Adcendo's ADCE-T02 in a new Phase Ib study in patients with advanced solid tumors. Adcendo sponsors the trial. First patient dosing anticipated in 2H 2026.

2HJ HyupJin
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-21
Description

Distribution partnership with Ysios portfolio company Inbiomotion to offer the MAF Test® in South Korea. The MAF Test® will benefit an estimated 34,000 new breast cancer patients each year in South Korea. HJ HyupJin is a Seoul-based South Korean healthcare and precision diagnostics company.

ysioscapital.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-20
Description

Research collaboration with Ysios portfolio company Synendos Therapeutics for the Phase 2 efficacy and safety clinical trial in patients with Generalized Anxiety Disorder (GAD). Professor Allan Young (Chair of Academic Psychiatry at Imperial College London) at King's College London leads the evaluation of Synendos' lead SERI molecule SYT-510. This is the first time a SERI molecule is dosed in a patient population.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-27
Description

Ysios Capital works closely with IRB Barcelona (and ICREA) through multiple portfolio companies including Ona Therapeutics (spin-off of ICREA and IRB Barcelona, based at Barcelona Science Park) and Inbiomotion (spin-off of IRB Barcelona and ICREA, founded 2011 by Dr. Roger Gomis). InceptionBio fund also engages with research institutions to translate scientific discoveries into therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-27
Description

Ysios Capital works closely with ICREA through multiple portfolio companies including Ona Therapeutics and Inbiomotion (both spin-offs of ICREA and IRB Barcelona). The InceptionBio fund aims to identify and develop new companies around scientific assets emerging from research institutions including ICREA-affiliated researchers.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Ysios Capital acts as investment advisor to the Telescope Biotech Fund, a listed biotech fund managed by Andbank Wealth Management (<https://andbank.es/boutiquehub/ysios/>). The partnership allows Ysios to provide investment advisory services to a publicly distributed fund product.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-18
Description

Distribution partnership with Ysios portfolio company Inbiomotion for Spain and Portugal to distribute the MAF Test® diagnostic.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-18
Description

Distribution partnership with Ysios portfolio company Inbiomotion for the United Kingdom and Ireland to distribute the MAF Test® diagnostic.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-18
Description

Distribution partnership with Ysios portfolio company Inbiomotion for Italy to distribute the MAF Test® diagnostic.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-18
Description

Distribution partnership with Ysios portfolio company Inbiomotion for Sub-Saharan Africa to distribute the MAF Test® diagnostic.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-12-18
Description

Antibody agreement with Ysios portfolio company Ona Therapeutics to develop antibody-drug conjugates (ADCs) targeting solid tumors. Biocytogen granted Ona access to evaluate Biocytogen's proprietary RenMice®-derived fully human antibodies against a specific tumor target.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Forbion is a leading European life sciences venture capital firm managing multiple funds and specializing in early- and late-stage biotech and medtech investments across therapeutic areas similar to Ysios's portfolio. Directly comparable in fund size (€2B+ AUM) and European biotech focus.

TypeDirect peer
Description

Jeito Capital is a European life sciences VC firm investing in biotech and medtech companies across Europe and the US. Led the $75M Series C for Adcendo with Ysios as co-investor, demonstrating direct syndicate overlap and similar focus on therapeutics for high unmet medical need.

TypeDirect peer
Description

Sofinnova Partners is one of Europe's oldest life sciences VC firms investing in therapeutics and medtech from early-stage through late-stage. Comparable geographic footprint, fund size, and therapeutic focus to Ysios Capital.

TypeDirect peer
Description

Gilde Healthcare is a European healthcare and life sciences investor with dedicated biotech and medtech funds, participating in rounds alongside Ysios (e.g., Adcendo Series C). Similar mandate covering therapeutics, diagnostics and medical devices.

TypeDirect peer
Description

HealthCap is a Nordic/European life sciences VC firm investing in late-stage biotech and medtech. Co-invested in Adcendo Series C with Ysios, with similar portfolio construction in clinical-stage therapeutics.

TypeDirect peer
Description

Novo Holdings is a Danish life sciences investor operating venture arms (Novo Seeds, Novo Ventures) that invest in early- and late-stage biotech. Participated alongside Ysios in Adcendo Series C, and shares Danish biotech overlap (e.g., Adcendo, Cytoki Pharma).

TypeDirect peer
Description

Asabys Partners is a Barcelona-based life sciences VC firm investing in therapeutics, medtech and digital health. Direct co-investor with Ysios in Ona Therapeutics and other Spanish/European biotech, with similar early-stage focus and Spanish ecosystem presence.

TypeDirect peer
Description

Alta Life Sciences is a Spanish life sciences VC firm investing in early- to mid-stage biotech companies. Frequently co-invests with Ysios in portfolio companies (e.g., Ona Therapeutics) and shares the Spanish biotech focus.

TypeDirect peer
Description

Columbus Venture Partners is a Spanish venture capital firm specialized in life sciences and biotech. Co-led Ona Therapeutics' $86.6M Series B with Ysios participating, sharing Spanish/European biotech focus and stage mandate.

TypeDirect peer
Description

Mérieux Equity Partners is a European PE/VC firm with a dedicated healthcare and life sciences strategy. Co-led Ona Therapeutics' $86.6M Series B with Ysios, with comparable European healthcare investment focus and stage range.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers29 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment85 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ysios Capital

Life Sciences Venture Capitalysioscapital.com

Ysios Capital is a Spanish life sciences venture capital firm founded in 2008 that provides private equity financing to early- and mid-stage biotech, medical device, and diagnostics companies across Europe and the United States, managing over €400M across three VC funds plus the InceptionBio company-creation fund.

What Ysios Capital does

Ysios Capital Partners, S.G.E.I.C., S.A.U. is a Spanish life sciences venture capital firm founded in 2008 and headquartered in San Sebastián, with a second office in Barcelona. The firm provides private equity financing to early- and mid-stage biotechnology, medical device, diagnostics, and digital therapeutics companies developing therapies for indications with high unmet medical need, with portfolio companies located across Europe and the United States. Ysios manages over €400 million in assets across three venture capital funds, acts as investment advisor to the listed Telescope Biotech Fund managed by Andbank Wealth Management, and in March 2026 launched InceptionBio, a €100 million target-size fund focused on biotech company creation in Spain in partnership with CDTI.

The firm invests across the full life sciences value chain, from academic spin-offs (e.g., IRB Barcelona/ICREA spin-offs Inbiomotion and Ona Therapeutics) through clinical-stage and NASDAQ-listed companies (Aura Biosciences, Fusion Pharmaceuticals, KALA BIO, LAVA Therapeutics, Mineralys Therapeutics), with a portfolio of 42+ companies, 19 products brought to market, and over 70 products at clinical stage. Ysios has completed six NASDAQ exits and ten M&A transactions, including Takeda's acquisition of TiGenix (~€450M), Vifor Pharma's acquisition of Sanifit (€375M), and Qiagen's purchase of STAT-Diagnostica (€172M).

Revenue is generated through management fees on its three VC funds and the InceptionBio vehicle, plus investment advisory fees on the listed Telescope Biotech Fund, with potential carried interest participation through portfolio exits. The firm operates a proprietary Y-mpact impact measurement methodology with a public Y-Score assessment tool (1-5 stars across Innovation, Social, and Governance pillars), and is supported by the European Investment Fund (EIF), CDTI, and the European Union. Distribution is conducted through direct project submissions, direct investment with board representation, public-private co-investment via CDTI's SICC Innvierte program, and wealth-management distribution via Andbank.

Ysios Capital firmographics

Firmographics
Name
Ysios Capital
Legal name
Ysios Capital Partners, S.G.E.I.C., S.A.U.
Website
https://ysioscapital.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
Ysios Capital is a Spanish life sciences venture capital firm founded in 2008 that provides private equity financing to early- and mid-stage biotech, medical device, and diagnostics companies across Europe and the United States, managing over €400M across three VC funds plus the InceptionBio company-creation fund.
Ownership category
akta.pro rank

Ysios Capital industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Portfolio Management and Investment Advice (523940), Funds, Trusts, and Other Financial Vehicles (525)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
SECONDARYFSANAAAC
Late-Stage Venture Capital (Series C+)

Keywords

  • Life sciences venture capital
  • Biotech private equity
  • Venture capital funds
  • Biotech company creation
  • Healthcare growth equity

Where Ysios Capital is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Ysios Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Fund Management Fees: Ysios Capital generates revenue through management fees on three venture capital funds with over €400 million in assets under management, plus investment advisory fees on the Telescope Biotech Fund (a listed biotech fund managed by Andbank Wealth Management). A new €100 million target-size fund (InceptionBio) was launched in March 2026, with first closing already completed via CDTI's SICC Innvierte program.
  2. Carried Interest / Fund Returns: As a venture capital firm, Ysios Capital participates in fund returns through exits in its portfolio companies. The firm has completed six NASDAQ exits and ten M&A transactions, including landmark deals such as Takeda's acquisition of Tigenix (approximately €450M), Qiagen's purchase of STAT-Diagnostica (€172M), and Vifor Pharma's acquisition of Sanifit (€375M).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractFund terms and management fees are not publicly disclosed

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

Ysios Capital product offering

Product offering

Core offering

Ysios Capital is a European life sciences venture capital firm that provides private equity financing to early- and mid-stage biotech companies developing novel therapies for indications with high unmet medical need. It manages over €400 million across three venture capital funds, supplements this with a €100M InceptionBio company-creation fund, and acts as investment advisor to the listed Telescope Biotech Fund managed by Andbank Wealth Management. The firm combines capital with scientific, financial and operational expertise, supported by a proprietary Y-mpact impact measurement methodology.

Product overview

Ysios Capital is a Spanish/European life sciences venture capital firm whose offering is a platform-plus-modules investment architecture rather than a single SaaS product: (a) the core product is its three venture capital funds providing private equity financing to early- and mid-stage life sciences companies, supplemented by the InceptionBio €100M company-creation fund launched in March 2026 and the Telescope Biotech Fund advisory mandate; (b) proprietary differentiated capabilities include the in-house Y-mpact / Y-Score impact measurement methodology and public Y-Score Test tool, and the Whistleblowing Channel compliance service operated under Spanish Act 2/2023; and (c) supporting infrastructure includes the Valuat-based investor portal at ysios.valuat.com for fund reporting. These offerings collectively span the full life sciences investment value chain — from company creation through clinical-stage development — and serve limited partners/investors, portfolio companies and internal compliance stakeholders.

Differentiator

Problem solved

Functional benefit

Brands

  • Y-mpact: Ysios' proprietary in-house methodology to measure the impact of investment activity across Innovation, Social and Governance (ISG) pillars.
  • Y-Score
  • InceptionBio

Products and services

  • InceptionBio fund New €100M target-size fund launched in March 2026 focused on biotech company creation and early-stage projects in Spain, co-led by Managing Partner Joan Perelló and Partner Arturo Urrios, with first closing via CDTI SICC Innvierte. Aims to create at least three new biotech companies in 2026 by working with universities, research centers and scientific entrepreneurs on technology transfer.
  • Ysios Capital venture capital funds (three funds) Core private equity product providing financing to early- and mid-stage highly innovative life sciences companies developing therapies for indications with high unmet medical need. Manages over €400 million in assets across three venture capital funds and has invested in more than 40 biotech companies, achieving six NASDAQ exits and ten M&A transactions (Tigenix/Takeda ~€450M, STAT-Diagnostica/Qiagen €172M, Sanifit/Vifor €375M).
  • Telescope Biotech Fund Listed biotech fund managed by Andbank Wealth Management for which Ysios Capital acts as investment advisor, complementing its direct venture capital investment strategy. Distributed via Andbank's wealth management platform.
  • Y-mpact / Y-Score impact measurement In-house proprietary methodology that measures the impact of Ysios's investment activity across three pillars — Innovation, Social and Governance (ISG) — producing a Y-Score rated from 1 (low) to 5 (very high) stars per pillar and as a weighted overall score. Includes a public-facing Y-Score Test questionnaire accessible at ysioscapital.com/measure-your-y-score/.
  • Whistleblowing Channel Internal reporting system implemented under Spanish Act 2/2023 (transposing EU Directive 2019/1937), enabling confidential and anonymous reporting of regulatory breaches, with Wen Wen Cheng (Head of Legal) appointed as Whistleblowing Channel Manager. Covers Ysios, its venture capital funds and managed closed-end collective investment schemes.
  • Investor portal (Valuat) Secure online login portal at ysios.valuat.com that provides Ysios Capital investors with access to fund and portfolio reporting.

Companies that use Ysios Capital

Customer profile

Named customers29 records

Segments6 records

Ideal customer profiles3 records

Ysios Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ysios Capital partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship and core.

  • MSD (Merck & Co., Inc.)flagshipStrategic or Co-development Partner · 26 May 2026Clinical trial collaboration and supply agreement with Ysios portfolio company Adcendo ApS. MSD provides pembrolizumab (KEYTRUDA®) to be evaluated in combination with Adcendo's ADCE-T02 in a new Phase Ib study in patients with advanced solid tumors. Adcendo sponsors the trial. First patient dosing anticipated in 2H 2026.
  • HJ HyupJincoreChannel Partner/ Reseller/ Distributor · 21 May 2026Distribution partnership with Ysios portfolio company Inbiomotion to offer the MAF Test® in South Korea. The MAF Test® will benefit an estimated 34,000 new breast cancer patients each year in South Korea. HJ HyupJin is a Seoul-based South Korean healthcare and precision diagnostics company.
  • King's College London (Prof. Allan Young)coreStrategic or Co-development Partner · 20 May 2026Research collaboration with Ysios portfolio company Synendos Therapeutics for the Phase 2 efficacy and safety clinical trial in patients with Generalized Anxiety Disorder (GAD). Professor Allan Young (Chair of Academic Psychiatry at Imperial College London) at King's College London leads the evaluation of Synendos' lead SERI molecule SYT-510. This is the first time a SERI molecule is dosed in a patient population.
  • IRB BarcelonacoreStrategic or Co-development Partner · 27 March 2026Ysios Capital works closely with IRB Barcelona (and ICREA) through multiple portfolio companies including Ona Therapeutics (spin-off of ICREA and IRB Barcelona, based at Barcelona Science Park) and Inbiomotion (spin-off of IRB Barcelona and ICREA, founded 2011 by Dr. Roger Gomis). InceptionBio fund also engages with research institutions to translate scientific discoveries into therapies.
  • ICREA (Catalan Institution for Research and Advanced Studies)coreStrategic or Co-development Partner · 27 March 2026Ysios Capital works closely with ICREA through multiple portfolio companies including Ona Therapeutics and Inbiomotion (both spin-offs of ICREA and IRB Barcelona). The InceptionBio fund aims to identify and develop new companies around scientific assets emerging from research institutions including ICREA-affiliated researchers.
  • Andbank Wealth ManagementflagshipStrategic or Co-development Partner · 18 March 2026Ysios Capital acts as investment advisor to the Telescope Biotech Fund, a listed biotech fund managed by Andbank Wealth Management (<https://andbank.es/boutiquehub/ysios/>). The partnership allows Ysios to provide investment advisory services to a publicly distributed fund product.
  • Palex MedicalcoreChannel Partner/ Reseller/ Distributor · 18 September 2025Distribution partnership with Ysios portfolio company Inbiomotion for Spain and Portugal to distribute the MAF Test® diagnostic.
  • Source BioSciencecoreChannel Partner/ Reseller/ Distributor · 18 September 2025Distribution partnership with Ysios portfolio company Inbiomotion for the United Kingdom and Ireland to distribute the MAF Test® diagnostic.
  • SPA FarmacoreChannel Partner/ Reseller/ Distributor · 18 September 2025Distribution partnership with Ysios portfolio company Inbiomotion for Italy to distribute the MAF Test® diagnostic.
  • The Scientific GroupcoreChannel Partner/ Reseller/ Distributor · 18 September 2025Distribution partnership with Ysios portfolio company Inbiomotion for Sub-Saharan Africa to distribute the MAF Test® diagnostic.
  • BiocytogencoreTechnology or Integration · 18 December 2023Antibody agreement with Ysios portfolio company Ona Therapeutics to develop antibody-drug conjugates (ADCs) targeting solid tumors. Biocytogen granted Ona access to evaluate Biocytogen's proprietary RenMice®-derived fully human antibodies against a specific tumor target.

Scale indicators19 records

Recent moves7 records

Expansion highlights6 records

Ysios Capital competitors and assessment

Company assessment

Direct peers

  • Forbion: Forbion is a leading European life sciences venture capital firm managing multiple funds and specializing in early- and late-stage biotech and medtech investments across therapeutic areas similar to Ysios's portfolio. Directly comparable in fund size (€2B+ AUM) and European biotech focus.
  • Jeito Capital: Jeito Capital is a European life sciences VC firm investing in biotech and medtech companies across Europe and the US. Led the $75M Series C for Adcendo with Ysios as co-investor, demonstrating direct syndicate overlap and similar focus on therapeutics for high unmet medical need.
  • Sofinnova Partners: Sofinnova Partners is one of Europe's oldest life sciences VC firms investing in therapeutics and medtech from early-stage through late-stage. Comparable geographic footprint, fund size, and therapeutic focus to Ysios Capital.
  • Gilde Healthcare: Gilde Healthcare is a European healthcare and life sciences investor with dedicated biotech and medtech funds, participating in rounds alongside Ysios (e.g., Adcendo Series C). Similar mandate covering therapeutics, diagnostics and medical devices.
  • HealthCap: HealthCap is a Nordic/European life sciences VC firm investing in late-stage biotech and medtech. Co-invested in Adcendo Series C with Ysios, with similar portfolio construction in clinical-stage therapeutics.
  • Novo Holdings (Novo Seeds/Novo Ventures): Novo Holdings is a Danish life sciences investor operating venture arms (Novo Seeds, Novo Ventures) that invest in early- and late-stage biotech. Participated alongside Ysios in Adcendo Series C, and shares Danish biotech overlap (e.g., Adcendo, Cytoki Pharma).
  • Asabys Partners: Asabys Partners is a Barcelona-based life sciences VC firm investing in therapeutics, medtech and digital health. Direct co-investor with Ysios in Ona Therapeutics and other Spanish/European biotech, with similar early-stage focus and Spanish ecosystem presence.
  • Alta Life Sciences: Alta Life Sciences is a Spanish life sciences VC firm investing in early- to mid-stage biotech companies. Frequently co-invests with Ysios in portfolio companies (e.g., Ona Therapeutics) and shares the Spanish biotech focus.
  • Columbus Venture Partners: Columbus Venture Partners is a Spanish venture capital firm specialized in life sciences and biotech. Co-led Ona Therapeutics' $86.6M Series B with Ysios participating, sharing Spanish/European biotech focus and stage mandate.
  • Mérieux Equity Partners: Mérieux Equity Partners is a European PE/VC firm with a dedicated healthcare and life sciences strategy. Co-led Ona Therapeutics' $86.6M Series B with Ysios, with comparable European healthcare investment focus and stage range.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ysios Capital social profiles

Digital presence

Ysios Capital compliance and trust

Trust signal

Compliance3 records

Ysios Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ysios Capital leadership team

Management profile

Number of profiles

Profiles9 records

Ysios Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ysios Capital M&A and investment

M&A and investment

M&A

Investments85 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ysios Capital

What does Ysios Capital do?

Ysios Capital is a European life sciences venture capital firm that provides private equity financing to early- and mid-stage biotech companies developing novel therapies for indications with high unmet medical need. It manages over €400 million across three venture capital funds, supplements this with a €100M InceptionBio company-creation fund, and acts as investment advisor to the listed Telescope Biotech Fund managed by Andbank Wealth Management. The firm combines capital with scientific, financial and operational expertise, supported by a proprietary Y-mpact impact measurement methodology.

Is Ysios Capital a public or private company?

Ysios Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Ysios Capital founded?

Ysios Capital was founded in 2008. It employs 11 to 50 people.

Where is Ysios Capital based?

Ysios Capital is headquartered in Barcelona, Spain, in the Europe region.

How does Ysios Capital make money?

Two revenue lines are on record. Fund Management Fees are the primary driver. The others are carried Interest / Fund Returns.

Who are Ysios Capital's main competitors?

Direct peers on record are Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, HealthCap, Novo Holdings (Novo Seeds/Novo Ventures), Asabys Partners, Alta Life Sciences, Columbus Venture Partners and Mérieux Equity Partners.

Does Ysios Capital have an API?

No public API is recorded for Ysios Capital.

What industry is Ysios Capital in?

Ysios Capital's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAC, Late-Stage Venture Capital (Series C+). Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mpo-magAnaconda Biomed Secures $56 Million in FinancingAnaconda Biomed closed a $56 million financing round led by Omega Funds and FOCO, with participation from Asabys, Ysios Capital, and CDTI. The funds will support product development and the ATHENA pivotal IDE study for its ANA Funnel Catheter. The company targets the large stroke intervention market, where nearly 270,000 mechanical thrombectomy procedures were performed in 2026.El ReferenteYsios Capital anuncia una nueva desinversión: Memo TherapeuticsIpsen acquired Memo Therapeutics, a Ysios Capital portfolio company, for an initial 200 million euros with milestones up to 700 million. The deal closes in Q3 2026, and Ysios Capital expects returns to increase if milestones are met. Memo's first-in-class drug potravitug targets BK virus in kidney transplant patients.El ReferenteYsios Capital anuncia una nueva desinversión: Memo TherapeuticsYsios Capital exited Memo Therapeutics after Ipsen acquired the company for €200 million upfront, with potential total value exceeding €700 million. The deal closes in Q3 2026, and Memo's first-in-class drug potravitug has FDA FastTrack and EU orphan drug designations. Non-potravitug assets will transfer to a new company, Memorises Bio.El ReferenteYsios Capital anuncia una nueva desinversión: Memo TherapeuticsIpsen acquired Memo Therapeutics for an initial 200 million euros, with additional payments up to 700 million euros. Ysios Capital, which invested in Memo in 2024, will exit the deal. The acquisition is expected to close in Q3 2026.El ReferenteYsios Capital anuncia una nueva desinversión: Memo TherapeuticsIpsen acquired Memo Therapeutics, a Ysios Capital portfolio company, for an initial 200 million euros with milestones up to 700 million. The deal closes in Q3 2026, and Ysios Capital expects a return for its investors. Memo's first-in-class drug potravitug targets BK virus in kidney transplant patients.WebcapitalriesgoYsios Capital anuncia una nueva desinversión tras la adquisición de Memo Therapeutics por IpsenIpsen, a global biopharmaceutical company, has agreed to acquire Memo Therapeutics AG for an upfront payment of €200 million with potential additional milestone payments reaching a total value exceeding €700 million, expected to close in Q3 2026 subject to customary conditions. The deal centers on potravitug, a first-in-class monoclonal antibody targeting BK polyomavirus infection in kidney transplant patients, a complication with no currently approved treatments that can lead to graft loss. Ysios Capital, which co-led Memo Therapeutics' Series C extension in 2024, announces this divestment representing a return for its Ysios BioFund III investors, with Ipsen planning to advance potravitug into a pivotal Phase II/III study this year.European Biotechnology8 European VC firms to watch in 2026Eight European VC firms are profiled for 2026, including Jeito Capital, Sofinnova Partners, and Medicxi, with fund sizes and recent exits. The list highlights firms that closed new biotech funds in the past year, such as Jeito II at $1.2 billion and Medicxi V at €500 million. The firms are positioned as shaping the continent's investment landscape amid tighter capital.InvestorsinhealthcareSpain: Ona Therapeutics raises US$86.6m Series B to advance First-in-Class ADCs into clinical developmentOna Therapeutics, a Spain-based biopharmaceutical company, closed an oversubscribed US$86.6m Series B financing. The round was co-led by new investors Columbus, with the funds intended to advance first-in-class ADCs into clinical development.Empresas de Capital Riesgo en EspaOna Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical DevelopmentOna Therapeutics closed an oversubscribed $86.6 million Series B, co-led by Columbus Venture Partners and Mérieux Equity Partners. The funds will advance ONA-255, a first-in-class ADC for breast cancer, and progress ONA-389 toward first-in-human studies for colorectal cancer.BioSpaceOna Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical DevelopmentOna Therapeutics closed an oversubscribed $86.6 million Series B financing co-led by Columbus Venture Partners and Mérieux Equity Partners. Proceeds will advance clinical development of its lead ADC ONA-255 in breast cancer and progress ONA-389 in colorectal cancer. The company retains full worldwide commercial rights to its assets.